Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line

Background and aim Vasculogenic mimicry (VM) is one of the most important causes of breast cancer metastasis and resistance against drugs. The cancer stem cells (CSCs) are known as essential factors for VM formation. In this study, the effects of melatonin, Apatinib, and a combination of Apatinib/me...

Full description

Saved in:

Bibliographic Details
Published in:	Breast cancer (Tokyo, Japan) Japan), 2022-03, Vol.29 (2), p.260-273
Main Authors:	Maroufi, Nazila Fathi, Rashidi, Mohsen, Vahedian, Vahid, Jahanbazi, Raheleh, Mostafaei, Sahar, Akbarzadeh, Maryam, Kazemzadeh, Hamid, Nejabati, Hamid-Reza, Isazadeh, Alireza, Rashidi, Mohammad-Reza, Nouri, Mohammad
Format:	Article
Language:	eng
Subjects:	Apoptosis Breast cancer Breast Neoplasms - pathology Cancer Research Cell Line, Tumor Female Health aspects Humans MCF-7 Cells Medicine Medicine & Public Health Melatonin Melatonin - pharmacology Melatonin - therapeutic use Metastasis Neoplastic Stem Cells - pathology Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - metabolism Oncology Original Article Proteins Pyridines Stem cells Surgery Surgical Oncology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background and aim Vasculogenic mimicry (VM) is one of the most important causes of breast cancer metastasis and resistance against drugs. The cancer stem cells (CSCs) are known as essential factors for VM formation. In this study, the effects of melatonin, Apatinib, and a combination of Apatinib/melatonin on VM formation were investigated by breast CSCs from breast cancer cell line. Materials and methods The percentage of CSCs was determined in two breast cancer cell lines (MCF-7 and MDA-MB-231) by flow cytometry. The effects of Apatinib, melatonin, and a combination of Apatinib/melatonin were evaluated on proliferation and viability, migration and invasion, apoptosis, and VM formation in MDA-MB-231 cells. Moreover, expression levels of the involved proteins in cancer cell proliferation and viability, CSCs, migration and invasion, and VM formation were evaluated by real-time polymerase chain reaction (RT-PCR) and western blotting methods. Results Results of the present study showed that melatonin and Apatinib reduced survival rate of CSCs in a dose- and time-dependent manner. Apatinib, melatonin, and a combination of Apatinib/melatonin inhibited proliferation of breast CSCs ( P ≤ 0.001). Formation of VM was decreased in the MDA-MB-231 cancer cell line treated with Apatinib and combination of Apatinib/melatonin. Apatinib and combination of Apatinib/melatonin reduced invasion of breast CSCs ( P ≤ 0.0001). Expression of vascular endothelial VE-cadherin, ephrinA2 receptor (EPHA2), p-PI3K/phosphoinositide-3 kinase (PI3K) and phospho-AKT (p-AKT)/AKT ratios was decreased under the influence of Apatinib and a combination of Apatinib/melatonin ( P ≤ 0.01). Conclusion Apatinib or a combination of Apatinib/melatonin may be used to manage patients with breast cancer. However, further studies are needed to identify anti-cancer mechanisms of melatonin and Apatinib for better management of the patients with breast cancer.
ISSN:	1340-6868 1880-4233